Art. 24 Directive (EU) 2001/83

In forcesince 20 Jan 2011cited 6×
1.

Without prejudice to paragraphs 4 and 5, a marketing authorisation shall be valid for five years.

2.

The marketing authorisation may be renewed after five years on the basis of a re-evaluation of the risk-benefit balance by the competent authority of the authorising Member State.

To this end, the marketing authorisation holder shall provide the national competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including the evaluation of data contained in suspected adverse reactions reports and periodic safety update reports submitted in accordance with Title IX, and information on all variations introduced since the marketing authorisation was granted, at least 9 months before the marketing authorisation ceases to be valid in accordance with paragraph 1.

3.

Once renewed, the marketing authorisation shall be valid for an unlimited period, unless the national competent authority decides, on justified grounds relating to pharmacovigilance, including exposure of an insufficient number of patients to the medicinal product concerned, to proceed with one additional five-year renewal in accordance with paragraph 2.

4.

Any authorisation which within three years of its granting is not followed by the actual placing on the market of the authorised product in the authorising Member State shall cease to be valid.

5.

When an authorised product previously placed on the market in the authorising Member State is no longer actually present on the market for a period of three consecutive years, the authorisation for that product shall cease to be valid.

6.

The competent authority may, in exceptional circumstances and on public health grounds grant exemptions from paragraphs 4 and 5. Such exemptions must be duly justified.

  • Directive (EU) 2004/27Lawamends

  • Directive (EU) 2010/84Lawamends

  • Medicines (Homoeopathic Medicinal Products for Human Use) Amendment Regulations 2005Law

    … the Homoeopathic Regulations dealing with renewal of certificates of registration in order to implement the changes to Article 24 of Directive 2001/83/EC and the insertion of Article 23a. Regulation 10 makes provision for the licensing …

  • Décret n° 2008-435 du 6 mai 2008 relatif à la mise sur le marché des spécialités pharmac…59Law

    … si le renouvellement dont une autorisation a fait l'objet a été effectué dans les conditions prévues à l'article 24 de la directive 2001/83/CE du Parlement européen et du Conseil du 6 novembre 2001 ; 2° Les autorisations de mise sur …

  • Opinion of Advocate General Sharpston delivered on 22 April 2010. European Commission v Republic of Lithuania.Decision

    It must be borne in mind that, if one of the existing 15 Member States authorised a medicinal product under Directive 2001/83, Article 24 of that Directive permitted it to maintain that product on the market for a period of five years, …

    22 Apr 2010 · 62008CC0350

  • Opinion of Advocate General Medina delivered on 6 October 2022. European Commission and Others v Pharmaceutical Works Polpharma S.A.Decision

    I should point out that the framework applicable in 2013 to the renewal of the marketing authorisation of Fumaderm includes, for instance, Article 24 of Directive 2001/83, which establishes the obligation incumbent on the national …

    6 Oct 2022 · 62021CC0438